SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!
廖妙菱
Lv1
90 积分
2021-01-08 加入
最近求助
最近应助
互助留言
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
11天前
已完结
The present and future of bispecific antibodies for cancer therapy
11天前
已完结
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
11天前
已完结
OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
17天前
已完结
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)]
17天前
已完结
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
1个月前
已完结
2023 FDA approvals
1个月前
已完结
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
1个月前
已完结
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
2个月前
已完结
Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma
3个月前
已完结
没有进行任何应助
没有进行任何互助留言
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论